Related Experiment Videos
A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma
Louis-Philippe Boulet1, Eric D Bateman, Robert Voves
1Institut de cardiologie et de pneumologie de l'Université Laval, Hôpital Laval, 2725 Chemin Sainte-Foy, Québec City, Que., Canada G1V 4G5. lpboulet@med.ulaval.ca
Respiratory Medicine
|April 24, 2007
Summary
Once-daily ciclesonide and twice-daily fluticasone propionate offer similar lung function improvements for moderate persistent asthma. Ciclesonide demonstrated better outcomes in oral candidiasis and quality of life.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Moderate persistent asthma requires effective inhaled corticosteroid (ICS) therapy.
- Comparing different ICS dosing regimens is crucial for optimizing patient care.
Purpose of the Study:
- To evaluate the efficacy and safety of once-daily ciclesonide versus twice-daily fluticasone propionate in adults with moderate persistent asthma.
Main Methods:
- A 12-week, randomized, open-label study compared ciclesonide 320 mcg once daily to fluticasone propionate 200 mcg twice daily.
- Inclusion criteria included age 12-75 years and moderate persistent asthma based on FEV1 and symptom/rescue medication use.
- The primary endpoint was the change from baseline in forced expiratory volume in 1s (FEV1).
Main Results:
- Both treatments significantly improved FEV1 from baseline.
- Once-daily ciclesonide was non-inferior to twice-daily fluticasone propionate regarding FEV1.
- Ciclesonide showed significantly greater improvements in health-related quality of life and a lower incidence of oral candidiasis compared to fluticasone propionate.
Conclusions:
- Once-daily ciclesonide provides comparable lung function benefits to twice-daily fluticasone propionate for moderate persistent asthma.
- Ciclesonide offers advantages in reducing oral candidiasis and enhancing quality of life.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...